Trial Profile
A single-arm, multicenter, phase II clinical study to evaluate the efficacy and safety of GLS-010 injection in the treatment of recurrent or refractory classical Hodgkin's lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Jul 2022
Price :
$35
*
At a glance
- Drugs Zimberelimab (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Sponsors Guangzhou Gloria Biosciences
- 07 Jun 2022 Results of a pooled analysis (NCT03722147, NCT03209973, NCT03155425 and NCT03655483) assessing the survival outcome of patients with relapsed or refractory classical Hodgkin lymphoma who achieved remission during immune checkpoint inhibitors treatment presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 27 Aug 2021 Results assessing the efficacy and safety of GLS-010 (zimberelimab) in patients with r/r-cHL published in the European Journal of Cancer
- 08 Dec 2020 Preliminary results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology